Vitalea Science Partners With SGS Life Science Services to Provide Microdosing Studies

SGS announces that its Life Science Services division has selected Vitalea Science as a partner for providing Microdosing studies based on the Accelerator Mass Spectrometry (AMS) technology. This partnership further strengthens the complementary services offered by both SGS and Vitalea in executing early clinical trials based on the exploratory-IND concept.

(PRWEB) November 2, 2007 -- SGS announces that its Life Science Services division has selected Vitalea Science as a partner for providing Microdosing studies based on the Accelerator Mass Spectrometry (AMS) technology. This partnership further strengthens the complementary services offered by both SGS and Vitalea in executing early clinical trials based on the exploratory-IND concept.

Within the past three years, early phase clinical trials (Phase I-IIa) have evolved in process and purpose. New technology applications and shifts in the traditional drug development paradigm allow more information about drug candidates to be captured earlier in the process. By harnessing the power of the AMS atom counter, one is able to collect ADME, bioavailability, and pharmacokinetic evaluations at the very earliest stages of clinical drug development: Phase 0 microdosing and Phase I microtracing. Streamlining early clinical development with microdosing and microtracers enables better development decisions, increasing potential success while reducing costs of failure for new drugs, formulations and delivery strategies.

In partnering with Vitalea Science, SGS is able to combine its own state of the art Phase I and bioanalytical facilities with Vitalea's AMS technology to provide clients with the necessary tools to execute these microdosing and microtracing studies. With new regulations in place as of June 2007, these exploratory IND studies can now be executed in SGS' Belgian facility. Clients benefit from working with two experienced service providers ensuring expert scientific and technical consulting along with high quality and timely clinical trial execution.

Vitalea Science is a leading developer and provider of bioanalytical measurements for drug development and biological research using Accelerator Mass Spectrometry, a highly specialized blend of ion beam physics and mass spectrometry that enables ADME profiling both during and before Phase I clinical testing. Vitalea Science is at the forefront of a shift in the way drugs are developed and has assembled an experienced group of AMS investigators to expand the industry's capabilities and knowledge base. With studies completed in U.S., Europe and Japan, Vitalea has established a global and growing list of clients. Consistent with its leadership position, Vitalea has participated in pioneering paediatric studies made possible through its AMS technology platform, and continues to innovate through research grants and collaborations with Academic Institutes. Vitalea Science was founded in 2003 and is headquartered in northern California.

Learn more about Vitalea Science at www.vitaleascience.com

SGS Life Science Services, a Business unit of the SGS Group, has 30 years of experience as a global Contract Research Organization (CRO) providing a large range of services from preclinical activities to Phase I through IV trials, bioanalytical and QC testing. With more than 1,300 employees in LSS and 2,000 trials performed, SGS Life Science Services serves the pharmaceutical, biotechnology and medical device industries.

SGS Life Science Services' early phase facilities include two Phase I units, with a total of 162 beds, and four bioanalytical labs. Through years of executing complex trials SGS has a wealth of expertise in QT/QTc prolongation, radio-labeled C14 ADME & PET scan trials. Rapid access to special patient populations provides clients with the recruitment edge to execute time-critical trials, including pediatric, renal & hepatic impaired, postmenopausal and sterilized women, elderly and slow metabolizer patients. SGS offers extensive Bioanalytical capabilities and services, featuring mass spectrometry and immunoanalysis, including R&D capabilities for NCE's, hormones & biomarkers and a library of over 600 methods.

Additional information about SGS is available at www.sgs.com/lifescience

The SGS Group is the global leader and innovator in inspection, verification, testing and certification services. Founded in 1878, SGS is recognized as the global benchmark in quality and integrity. With more than 48'000 employees, SGS operates a network of over 1'000 offices and laboratories around the world.

###

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.